Literature DB >> 16511871

Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes.

Jean-Sébastien Walczak1, Vincent Pichette, François Leblond, Karine Desbiens, Pierre Beaulieu.   

Abstract

Neuropathic pain is one of the most inextricable problems encountered in clinics, because few facts are known about its etiology. Nerve injury often leads to allodynia and hyperalgesia, which are symptoms of neuropathic pain. The aim of this study was to understand some molecular and electrophysiological mechanisms of neuropathic pain after chronic constriction of the saphenous nerve (CCS) in mice. After surgery, CCS mice displayed significant allodynia and hyperalgesia, which were sensitive to acute systemic injection of morphine (4 mg/kg), gabapentin (50 mg/kg), amitriptyline (10 mg/kg), and the cannabinoid agonist WIN 55,212-2 (5 mg/kg). These behavioral changes were accompanied after surgery by an increase of c-Fos expression and by an overexpression of mu-opioid and cannabinoid CB1 and CB2 receptors in the spinal cord and the dorsal hind paw skin. In combination with the skin-nerve preparation, this model showed a decrease in functional receptive fields downstream to the injury and the apparition of A-fiber ectopic discharges. In conclusion, CCS injury induced behavioral, molecular, and electrophysiological rearrangements that might help us in better understanding the peripheral mechanisms of neuropathic pain. This model takes advantage of the possible use in the future of genetically modified mice and of an exclusively sensory nerve for a comprehensive study of peripheral mechanisms of neuropathic pain. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511871     DOI: 10.1002/jnr.20821

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  25 in total

1.  Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses.

Authors:  Katherine E Hanlon; Todd W Vanderah
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors.

Authors:  J Guindon; J Desroches; P Beaulieu
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

4.  Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.

Authors:  Michelle R Hoot; Laura J Sim-Selley; Justin L Poklis; Rehab A Abdullah; Krista L Scoggins; Dana E Selley; William L Dewey
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

Review 5.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

Review 6.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 7.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

Review 8.  Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain.

Authors:  Maulik D Jhaveri; Devi R Sagar; Steven J R Elmes; David A Kendall; Victoria Chapman
Journal:  Mol Neurobiol       Date:  2007-10-02       Impact factor: 5.590

9.  Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model.

Authors:  J Desroches; J Guindon; C Lambert; P Beaulieu
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

Review 10.  Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

Authors:  Elizabeth J Rahn; Andrea G Hohmann
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.